The incidence of diabetes is increasing globally; the estimated prevalence in 2010 being 285 million worldwide (www.http://diabetes.org.uk). In the UK alone, the number of people diagnosed with diabetes has increased from 1.4 to 2.6 million since 1996 (www.http://diabetes.org.uk). These individuals are at high risk of cardiovascular disease and in this population coronary artery disease (CAD) is common, regularly manifesting itself earlier in life than in individuals without diabetes . While strategies that maintain tight glucose control have been reported to ameliorate some of the microvascular complications of diabetes (retinopathy, nephropathy, neuropathy) , this approach appears to have little or no benefit in the macrovasculature . A greater understanding of the complexity of the diabetic milieu may therefore be invaluable in exposing therapeutic targets to reduce the incidence of macrovascular diseases in diabetes.
|Title of host publication||Diabetes & C-Peptide: Scientific and Clinical Aspects|
|Editors||Anders A.F. Sima|
|Publisher||Humana Press Inc.|
|Number of pages||16|
|Publication status||Published - 28 Oct 2011|
Porter, K. E., & Mughal, R. S. (2011). C-Peptide: Connecting diabetes with macrovascular complications. In A. A. F. Sima (Ed.), Diabetes & C-Peptide: Scientific and Clinical Aspects (pp. 129-144). Humana Press Inc.. https://doi.org/10.1007/978-1-61779-391-2_11